BACKGROUND: Pancreatic neuroendocrine neoplasms are rare malignancies for which the ideal staging method remains controversial. Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis in neuroendocrine neoplasms. We sought to test the predictive ability of Ki-67 staining for disease recurrence and overall survival (OS) in pancreatic neuroendocrine neoplasms. METHODS: The medical records of patients who underwent pancreatic resection for pancreatic neuroendocrine neoplasms at a tertiary referral hospital from 1994 to 2009 were reviewed. The pathologic specimens of all were stained for Ki-67 and recorded as percentage of cells staining positive per high-powered field. The 10-year disease-free and OSs were analyzed. RESULTS: We identified 140 patients. Gender and age were not associated with increased risk of disease recurrence. Patients with tumors >4 cm or with Ki-67 staining >9% were more likely to have disease recurrence (P = .0454 and .047) and have decreased OS (P < .0001 and .0007). CONCLUSION: Increasing tumor size and increasing Ki-67 staining both correlate with increased risk of disease recurrence and decreased OS. Designing a staging system that incorporates both of these clinical variables will enable better identification of patients at risk for recurrent pancreatic neuroendocrine neoplasms. Published by Mosby, Inc.
BACKGROUND:Pancreatic neuroendocrine neoplasms are rare malignancies for which the ideal staging method remains controversial. Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis in neuroendocrine neoplasms. We sought to test the predictive ability of Ki-67 staining for disease recurrence and overall survival (OS) in pancreatic neuroendocrine neoplasms. METHODS: The medical records of patients who underwent pancreatic resection for pancreatic neuroendocrine neoplasms at a tertiary referral hospital from 1994 to 2009 were reviewed. The pathologic specimens of all were stained for Ki-67 and recorded as percentage of cells staining positive per high-powered field. The 10-year disease-free and OSs were analyzed. RESULTS: We identified 140 patients. Gender and age were not associated with increased risk of disease recurrence. Patients with tumors >4 cm or with Ki-67 staining >9% were more likely to have disease recurrence (P = .0454 and .047) and have decreased OS (P < .0001 and .0007). CONCLUSION: Increasing tumor size and increasing Ki-67 staining both correlate with increased risk of disease recurrence and decreased OS. Designing a staging system that incorporates both of these clinical variables will enable better identification of patients at risk for recurrent pancreatic neuroendocrine neoplasms. Published by Mosby, Inc.
Authors: Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra Journal: J Clin Oncol Date: 2002-06-01 Impact factor: 44.544
Authors: A Gentil Perret; J F Mosnier; J P Buono; P Berthelot; J Chipponi; J G Balique; J Cuilleret; P Dechelotte; S Boucheron Journal: Am J Clin Pathol Date: 1998-03 Impact factor: 2.493
Authors: Robert C G Martin; David A Kooby; Sharon M Weber; Nipun B Merchant; Alex A Parikh; Clifford S Cho; Syed A Ahmad; Hong Jin Kim; William Hawkins; Charles R Scoggins Journal: J Gastrointest Surg Date: 2010-11-20 Impact factor: 3.452
Authors: G Pelosi; E Bresaola; G Bogina; F Pasini; S Rodella; P Castelli; C Iacono; G Serio; G Zamboni Journal: Hum Pathol Date: 1996-11 Impact factor: 3.466
Authors: Nikiforos Ballian; Agnes G Loeffler; Victoria Rajamanickam; Peter A Norstedt; Sharon M Weber; Clifford S Cho Journal: HPB (Oxford) Date: 2009-08 Impact factor: 3.647
Authors: Karl Y Bilimoria; David J Bentrem; Ryan P Merkow; James S Tomlinson; Andrew K Stewart; Clifford Y Ko; Mark S Talamonti Journal: J Am Coll Surg Date: 2007-08-03 Impact factor: 6.113
Authors: Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra Journal: Am J Surg Pathol Date: 2015-05 Impact factor: 6.394
Authors: Chad M McCall; Chanjuan Shi; Toby C Cornish; David S Klimstra; Laura H Tang; Olca Basturk; Liew Jun Mun; Trevor A Ellison; Christopher L Wolfgang; Michael A Choti; Richard D Schulick; Barish H Edil; Ralph H Hruban Journal: Am J Surg Pathol Date: 2013-11 Impact factor: 6.394
Authors: Yassar M Hashim; Kathryn M Trinkaus; David C Linehan; Steven S Strasberg; Ryan C Fields; Dengfeng Cao; William G Hawkins Journal: Ann Surg Date: 2014-02 Impact factor: 12.969
Authors: Javier A Cienfuegos; Joseba Salguero; Jorge M Núñez-Córdoba; Miguel Ruiz-Canela; Alberto Benito; Sira Ocaña; Gabriel Zozaya; Pablo Martí-Cruchaga; Fernando Pardo; José Luis Hernández-Lizoáin; Fernando Rotellar Journal: Surg Endosc Date: 2017-01-26 Impact factor: 4.584
Authors: Jan G D'Haese; Chiara Tosolini; Güralp O Ceyhan; Bo Kong; Irene Esposito; Christoph W Michalski; Jörg Kleeff Journal: World J Gastroenterol Date: 2014-10-14 Impact factor: 5.742
Authors: Kendall J Keck; Allen Choi; Jessica E Maxwell; Guiying Li; Thomas M O'Dorisio; Patrick Breheny; Andrew M Bellizzi; James R Howe Journal: Ann Surg Oncol Date: 2017-05-30 Impact factor: 5.344
Authors: Shonan Sho; Colin M Court; Paul Winograd; Paul A Toste; Joseph R Pisegna; Michael Lewis; Timothy R Donahue; Oscar J Hines; Howard A Reber; David W Dawson; James S Tomlinson Journal: J Gastrointest Surg Date: 2018-10-23 Impact factor: 3.452